Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide and Escitalopram in Rheumatoid Arthritis
NCT05480878Phase 3Completed
- Sponsor
- Tanta University
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nitazoxanide and Escitalopram oxalate oral solution in rheumatoid arthritis (RA) (3 arms), sponsored by Tanta University. Primary endpoints: Clinical Disease Activity Index at 12 weeks, Erythrocyte Sedimentation Rate at 12 weeks and 3 more. Started Dec 2022; status: completed.
02
Drugs
nitazoxanideEscitalopram oxalate oral solution
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05480878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480878.